Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)
PHASE3CompletedINTERVENTIONAL
Enrollment
285
Participants
Timeline
Start Date
May 23, 2016
Primary Completion Date
September 30, 2018
Study Completion Date
September 30, 2018
Conditions
Sleep Initiation and Maintenance DisordersAlzheimer Disease
Interventions
DRUG
Suvorexant
10 mg tablet (may be increased to 20 mg tablet)
DRUG
Placebo
Placebo to suvorexant
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT02750306 - Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061) | Biotech Hunter | Biotech Hunter